State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China; Macau Centre for Research and Development in Chinese Medicine, University of Macau, Macau, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
J Control Release. 2023 Jun;358:510-540. doi: 10.1016/j.jconrel.2023.05.007. Epub 2023 May 15.
The etiology of inflammatory bowel disease (IBD) is extremely complex and related to an excessive immune response that results in the pathologically release of reactive oxygen species (ROS) via tissue injury and chronic inflammation. Generally, excessive ROS production is one of the essential mediators for inflammatory pathogenesis. Targeting cumulate ROS to interrupt pathological inflammatory responses has been recognized as a feasible strategy for inflammatory suppression of IBD. Correspondingly, the overexpression of ROS can also trigger the drug release of novel drug delivery systems to alleviate IBD symptoms. In this review, we summarized the pathological production of endogenous ROS in IBD, discussed the enormous potential of multiple kinds of ROS-scavenging and ROS-triggering novel delivery systems for the treatment of IBD, including enzymology, metal, polyphenols, natural pigments, nitroxide radicals-contained and sulfide-loaded drug delivery systems, and other novel ROS-responsive materials to synthesize ROS-based drug delivery systems. We also summarized the immunomodulatory effects of ROS-targeted drug delivery systems for the treatment of IBD. Besides, based on the requirements of clinical applications and industrialization development, the challenges faced in the evolution of redox drug delivery systems were also discussed. Collectively, this review provides a reliable reference to the development of ROS-scavenging and ROS-triggering drug delivery systems for the medical intervention of IBD.
炎症性肠病（IBD）的病因极其复杂，与过度免疫反应有关，这种过度免疫反应导致活性氧物质（ROS）病理性释放，进而引发组织损伤和慢性炎症。一般来说，过量的 ROS 产生是炎症发病机制的重要介质之一。针对累积的 ROS 以阻断病理性炎症反应已被认为是抑制 IBD 的一种可行策略。相应地，ROS 的过度表达也可以触发新型给药系统的药物释放，从而缓解 IBD 症状。在这篇综述中，我们总结了 IBD 中内源性 ROS 的病理性产生，讨论了多种清除 ROS 和触发 ROS 的新型给药系统在治疗 IBD 方面的巨大潜力，包括酶学、金属、多酚、天然色素、含硝氧自由基和负载硫化物的给药系统以及其他新型 ROS 响应性材料来合成基于 ROS 的给药系统。我们还总结了 ROS 靶向给药系统治疗 IBD 的免疫调节作用。此外，基于临床应用和产业化发展的要求，还讨论了氧化还原给药系统进化所面临的挑战。总之，本综述为开发用于 IBD 医学干预的清除 ROS 和触发 ROS 的给药系统提供了可靠的参考。
